Date: 2018-06-05
Type of information: Opening of new premises
Compound:
Company: InflaRx (Germany)
Therapeutic area: Inflammatory diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On June 5, 2018, InflaRx announced that the company has opened a new research facility in Ann Arbor, Michigan, in the United States. The facility will be part of InflaRx Pharmaceuticals Inc., a wholly owned US subsidiary of the InflaRx N.V. group, and operations will serve to further develop and extend the company’s unique complement system-based therapeutics.
- Following InflaRx’s successful initial public offering on the Nasdaq exchange in November of last year and the recent successful follow-on offering, the opening of this research facility represents the continued growth of the Company’s presence in the US. The opening comes at a time when the company’s lead candidate, IFX-1 is advancing through clinical trials with phase 2B data for its lead indication, hidradenitis suppurativa, expected in the first half of 2019.
Financial terms:
Latest news:
Is general: Yes
